&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-04-07, 18:30

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
Danny Gaylord

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-01-27, 18:00

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
Conrad Southern

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-02, 02:05

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
Capemenoneise

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-02, 02:00

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-10-22, 18:00

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Conrad Southern

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-10-08, 18:00

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
Genie Cordner

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-10-03, 19:30

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
Dora Legere

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-21, 15:15

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
Genie Cordner

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-21, 15:10

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
Kia Stones

Popular Posts